Seven treatment regimens for metastatic castration-resistant prostate cancer (mCRPC) have shown survival improvements. This literature review of clinical trials involving those treatments includes only those that also use patient-reported outcomes (PROs) to assess treatment impact since 2010. Four of the seven offered varying levels of health-related quality of life (HRQoL) benefit and/or pain mitigation.
The results of the study show that including HRQoL and pain levels as outcome measures can offer a better understanding of treatment impact in mCRPC. Further research is needed to standardize the methods of using HRQoL and pain measures in clinical studies of mCRPC treatments.
The study is available online ahead of print publication in: Prostate Cancer and Prostatic Diseases.
Sorry, comments are closed for this post.